VentriPoint Diagnostics (VPT) Q3 2024 earnings summary

Executive summary

• Ventripoint Diagnostics focuses on commercializing AI-powered cardiac diagnostic tools, with recent product launches and regulatory clearances in the US, Canada, and EU for its VMS+ system.

• The company is shifting from R&D to commercial operations, expanding its sales and marketing teams, and targeting key markets in North America and Europe.

• Strategic collaborations with Ascend Cardiovascular and the Ollie Hinkle Heart Foundation aim to enhance product reach and clinical adoption.

• Ongoing clinical studies and reference site programs are supporting market penetration, especially in pediatric and congenital heart disease segments.

Financial highlights

• Revenue for the three and nine months ended September 30, 2024, was $64,507 and $95,172, respectively, compared to $7,781 for the nine months ended September 30, 2023.

• Net loss for the three and nine months ended September 30, 2024, was $1,251,079 and $3,859,958, respectively, compared to $1,174,285 and $3,634,823 for the same periods in 2023.

• Cash and cash equivalents decreased to $110,693 at September 30, 2024, from $1,294,346 at December 31, 2023.

• Cash used in operating activities was $2,665,385 for the nine months ended September 30, 2024, down from $2,812,122 in the prior year.

• Cash provided by financing activities was $1,492,958, mainly from convertible debenture issuances and option exercises.

Outlook and guidance

• The company is prioritizing commercial traction for VMS+ in key markets and expects to continue expanding its installed base and clinical collaborations.

• Management indicates the need for near-term capital raises to fund ongoing operations and commercialization efforts.

• Product development continues with the release of VMS+ V3.2 and submission of V4.0 for regulatory clearance.